Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]
In development
Reference number: GID-TA10868
Expected publication date:
Following advice received from the company, this appraisal has been rescheduled to align with latest regulatory expectations. The appraisal committee meeting is now scheduled to take place on 21 May 2026.